Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review.
Adrenal insufficiency
Dual-release hydrocortisone
Metabolism
Pharmacokinetic
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
28
09
2019
accepted:
03
01
2020
pubmed:
14
1
2020
medline:
22
6
2021
entrez:
14
1
2020
Statut:
ppublish
Résumé
Dual-release hydrocortisone is a new hydrocortisone formulation developed to improve the pharmacokinetic and the pharmacodynamic profiles and patient compliance. The aim of this review is to summarize the main knowledge on dual-release hydrocortisone, with particular attention to pharmacokinetics, metabolic and health-related quality-of-life aspects, bone health and drug safety.
Identifiants
pubmed: 31927751
doi: 10.1007/s12020-020-02187-7
pii: 10.1007/s12020-020-02187-7
doi:
Substances chimiques
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
507-515Références
S. Bensing, A.L. Hulting, E.S. Husebye, O. Kämpe, K. Løvås, Management of endocrine disease: epidemiology, quality of life and complications of primary adrenal insufficiency: a review. Eur. J. Endocrinol. 175, R107–R116 (2016). https://doi.org/10.1530/EJE-15-1242
doi: 10.1530/EJE-15-1242
pubmed: 27068688
W. Arlt, B. Allolio, Adrenal insufficiency. Lancet 361, 1881–1893 (2003)
doi: 10.1016/S0140-6736(03)13492-7
E.S. Husebye, B. Allolio, W. Arlt, K. Badenhoop, S. Bensing, C. Betterle, A. Falorni, E.H. Gan, A.L. Hulting, A. Kasperlik-Zaluska, O. Kämpe, K. Løvås, G. Meyer, S.H. Pearce, Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J. Intern. Med. 275, 104–115 (2014). https://doi.org/10.1111/joim
doi: 10.1111/joim
pubmed: 24330030
S.R. Bornstein, B. Allolio, W. Arlt, A. Barthel, A. Don-Wauchope, G.D. Hammer, E.S. Husebye, D.P. Merke, M.H. Murad, C.A. Stratakis, D.J. Torpy, Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 364–389 (2016). https://doi.org/10.1210/jc.2015-1710
doi: 10.1210/jc.2015-1710
pubmed: 26760044
R. Bergthorsdottir, M. Leonsson-Zachrisson, A. Odén, G. Johannsson, Premature mortality in patients with Addison’s disease: a population-based study. J. Clin. Endocrinol. Metab. 91, 4849–4853 (2006)
doi: 10.1210/jc.2006-0076
I.L. Ross, R. Bergthorsdottir, N.S. Levitt, D.A. Schatz, G. Johannsson, A.D. Marais, Increased cardiovascular risk in South African patients with Addison’s disease. Horm. Metab. Res. 45, 905–910 (2013). https://doi.org/10.1055/s-0033-1351259
doi: 10.1055/s-0033-1351259
pubmed: 23918685
I.L. Ross, R. Bergthorsdottir, N. Levitt, J.A. Dave, D. Schatz, D. Marais, G. Johannsson, Cardiovascular risk factors in patients with Addison’s disease: a comparative study of South African and Swedish patients. PLoS ONE 9, e90768 (2014). https://doi.org/10.1371/journal.pone.0090768
doi: 10.1371/journal.pone.0090768
pubmed: 24603607
pmcid: 3948337
H. Filipsson, J.P. Monson, M. Koltowska-Häggström, A. Mattsson, G. Johannsson, The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J. Clin. Endocrinol. Metab. 91, 3954–3961 (2006)
doi: 10.1210/jc.2006-0524
R. Giordano, S. Marzotti, M. Balbo, S. Romagnoli, E. Marinazzo, R. Berardelli, G. Migliaretti, A. Benso, A. Falorni, E. Ghigo, E. Arvat, Metabolic and cardiovascular profile in patients with Addison’s disease under conventional glucocorticoid replacement. J. Endocrinological Investig. 32, 917–923 (2009). https://doi.org/10.3275/6437
doi: 10.3275/6437
G. Johannsson, R. Bergthorsdottir, A.G. Nilsson, H. Lennernas, T. Hedner, S. Skrtic, Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur. J. Endocrinol. 161, 119–130 (2009). https://doi.org/10.1530/EJE-09-0170
doi: 10.1530/EJE-09-0170
pubmed: 19383806
R. Giordano, F. Guaraldi, R. Berardelli, I. Karamouzis, V. D’Angelo, C. Zichi, S. Grottoli, E. Ghigo, E. Arvat, Dual-release hydrocortisone in Addison’s disease - a review of the literature. Eur. Endocrinol. 10, 75–78 (2014). https://doi.org/10.17925/EE.2014.10.01.75
doi: 10.17925/EE.2014.10.01.75
pubmed: 29872468
pmcid: 5983101
G. Johannsson, A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, T. Olsson, O. Ragnarsson, M. Ryberg, J. Wahlberg, B.M. Biller, J.P. Monson, P.M. Stewart, H. Lennernäs, S. Skrtic, Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J. Clin. Endocrinol. Metab. 97, 473–481 (2012). https://doi.org/10.1210/jc.2011-1926
doi: 10.1210/jc.2011-1926
pubmed: 22112807
G. Johannsson, H. Lennernäs, C. Marelli, K. Rockich, S. Skrtic, Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study. Eur. J. Endocrinol. 175, 85–93 (2016). https://doi.org/10.1530/EJE-15-1212
doi: 10.1530/EJE-15-1212
pubmed: 27129362
pmcid: 5065076
F. Ceccato, E. Selmin, C. Sabbadin, M. Dalla Costa, G. Antonelli, M. Plebani, M. Barbot, C.Betterle, M. Boscaro, C. Scaroni, Improved salivary cortisol rhythm with dual-release hydrocortisone. Endocr. Connect. 7, 965–974 (2018). https://doi.org/10.1530/EC-18-0257
M. Quinkler, R. Miodini Nilsen, K. Zopf, M. Ventz, M. Øksnes, Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172, 619–626 (2015). https://doi.org/10.1530/EJE-14-1114
doi: 10.1530/EJE-14-1114
pubmed: 25656494
R. Giordano, F. Guaraldi, E. Marinazzo, F. Fumarola, A. Rampino, R. Berardelli, I. Karamouzis, M. Lucchiari, T. Manetta, G. Mengozzi, E. Arvat, E. Ghigo, Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison’s disease. Endocrine 51, 360–368 (2016). https://doi.org/10.1007/s12020-015-0681-z
doi: 10.1007/s12020-015-0681-z
pubmed: 26184416
A.M. Isidori, M.A. Venneri, C. Graziadio, C. Simeoli, D. Fiore, V. Hasenmajer, E. Sbardella, D. Gianfrilli, C. Pozza, P. Pasqualetti, S. Morrone, A. Santoni, F. Naro, A. Colao, R. Pivonello, A. Lenzi, Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 6, 173–185 (2018). https://doi.org/10.1016/S2213-8587(17)30398-4
doi: 10.1016/S2213-8587(17)30398-4
pubmed: 29229498
L.M. Mongioì, R.A. Condorelli, S. La Vignera, A.E. Calogero, Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life. Endocr. Connect. 7, 211–219 (2018). https://doi.org/10.1530/EC-17-0368
doi: 10.1530/EC-17-0368
pubmed: 29233815
V. Guarnotta, A. Ciresi, G. Pillitteri, C. Giordano, Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis. Clin. Endocrinol. (Oxf.). 88(5), 665–672 (2018). https://doi.org/10.1111/cen.13554
doi: 10.1111/cen.13554
pubmed: 29368442
V. Guarnotta, C. Di Stefano, A. Santoro, A. Ciresi, A. Coppola, C. Giordano, Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency. Endocr. Connect. 8(7), 853–862 (2019). https://doi.org/10.1530/EC-19-0176
doi: 10.1530/EC-19-0176
pubmed: 31252397
pmcid: 6599082
V. Guarnotta, M.I. Mineo, S. Radellini, G. Pizzolanti, C. Giordano, Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study. Ther. Adv. Endocrinol. Metab. 10, 2042018819871169 (2019). https://doi.org/10.1177/2042018819871169
doi: 10.1177/2042018819871169
pubmed: 31489172
pmcid: 6713956
A. Al Nofal, I. Bancos, K. Benkhadra, N.M. Ospina, A. Javed, E. Kapoor, K. Muthusamy, J.P. Brito, A.F. Turcu, Z. Wang, L. Prokop, D.Z. Erickson, A.N. Lteif, N. Natt, M.H. Murad, Glucocorticoid replacement regimens in chronic adrenal insufficiency: a systematic review and meta-analysis. Endocr. Pract. 23, 17–31 (2017). https://doi.org/10.4158/EP161428.OR
doi: 10.4158/EP161428.OR
pubmed: 27631672
V.B. Boesen, T. Christoffersen, T. Watt, S.W. Borresen, M. Klose, U. Feldt-Rasmussen, PlenadrEMA: effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments: a study protocol for an open-label switch pilot study. BMJ Open. 8(1), e019487 (2018). https://doi.org/10.1136/bmjopen-2017-019487
doi: 10.1136/bmjopen-2017-019487
pubmed: 29362269
pmcid: 5786125
V. Camozzi, C. Betterle, A.C. Frigo, V. Zaccariotto, M. Zaninotto, E. De Caneva, P. Lucato, W. Gomiero, S. Garelli, C. Sabbadin, M. Salvà, M.D. Costa, M. Boscaro, G. Luisetto, Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison’s disease on glucocorticoid and mineralocorticoid replacement therapy. Endocrine 59, 319–329 (2018). https://doi.org/10.1007/s12020-017-1380-8
doi: 10.1007/s12020-017-1380-8
pubmed: 28795340
S. Frara, S. Chiloiro, T. Porcelli, A. Giampietro, G. Mazziotti, L. De Marinis, A. Giustina, Bone safety of dual-release hydrocortisone in patients with hypopituitarism. Endocrine 60, 528–531 (2018). https://doi.org/10.1007/s12020-017-1512-1
doi: 10.1007/s12020-017-1512-1
pubmed: 29313195
D.A. Vassiliadi, S. Tsagarakis, Multiple benefits from dual release hydrocortisone: a “hard” view from bones. Endocrine 61, 177–179 (2018). https://doi.org/10.1007/s12020-018-1628-y
doi: 10.1007/s12020-018-1628-y
pubmed: 29774503
A.G. Nilsson, C. Marelli, D. Fitts, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, T. Olsson, O. Ragnarsson, M. Ryberg, J. Wahlberg, H. Lennernäs, S. Skrtic, G. Johannsson, Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency. Eur. J. Endocrinol. 171, 369–377 (2014). https://doi.org/10.1530/EJE-14-0327
doi: 10.1530/EJE-14-0327
pubmed: 24944332
pmcid: 4106399
A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, O. Ragnarsson, S. Skrtic, J. Wahlberg, H. Achenbach, S. Uddin, C. Marelli, G. Johannsson, Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study. Eur. J. Endocrinol. 176, 715–725 (2017). https://doi.org/10.1530/EJE-17-0067
doi: 10.1530/EJE-17-0067
pubmed: 28292927
pmcid: 5425941